Lupin’s €190m VISUfarma Deal Helps US De-Risking, Boosts Specialty Business

 
• By Vibha Ravi
  
Acquisition deal
Lupin Adds VISUfarma To Its Specialty Drugs Business In Europe (Shutterstock)

More from Deals

More from Business